This month, the first working meeting took place in London to assess the creation of a European registry of prevention in Alzheimer's disease; an initiative of the Barcelonaβeta Brain Research Center (BBRC), the research center of the Pasqual Maragall Foundation. The meeting, held on May 10th, was attended by the scientific director and the scientific manager of the BBRC, doctors José Luis Molinuevo and Karine Fauria, and representatives of reference centers, hospitals, associations of patients and pharmacists.
The objective of the seminar was to evaluate the current state of the European cohorts of research in prevention, such as the Alpha Study, and study the feasibility of harmonizing them in a European registry, in which anyone who fulfills the requisites requested can be targeted. Therefore, the existing resources were examined, some prevention trials were presented from the perspective of the pharmaceutical industry, and the possible legal and technological implications of the project were addressed. On behalf of BBRC, Dr. Molinuevo led the round table discussion, and Dr. Karine Fauria defended the need to design and carry out a strategy for capturing and loyalty of the future participants of the registry.
According to Dr. Molinuevo, the meeting "highlighted the need to create a European record open to all citizens, in which we can collect the same variables, and invite these people to participate in different research projects in Alzheimer's prevention." However, Molinuevo says that it will still be necessary to hold more meetings like this one to determine key aspects like who assumes the cost and how to transfer the success of American records to European
Institutions participating in the day
In addition to the BBRC, among the institutions participating at the seminar were the Alzheimer's Association, the Fidelity Biosciences Research Initiative, the Innovative Medicines Initiative, the Banner Alzheimer's Institute, the Alzheimer's Research Center, the Center for Dementia Prevention at the University of Edinburgh, the Karolinska Institut, Merck, Biogen, the Cologne University Hospital, the European Program for Research in Neurodegenerative Diseases (JPND), the University of Leicester, the University Hospital of Toulouse, Alzheimer Europe, Alzheimer's Research UK and the National Institute for Health Research UK.